GRAS blog

Who decides whether an ingredient belongs in our food? Many consumers would expect the answer to be the Food and Drug Administration.

Under the “Generally Recognized as Safe,” or GRAS, framework, the answer can be the company selling it.

Current rules allow companies to conclude that an ingredient’s intended use meets GRAS requirements without obtaining FDA approval or notifying the agency. That creates a gap between what consumers may assume about food oversight and what the system requires.

What GRAS actually requires

GRAS is a legal exemption from the usual food additive approval process. It requires qualified experts to generally recognize that a substance is safe under its intended conditions of use. Those conditions matter: a conclusion about one amount or application does not automatically cover every use.

For conclusions based on scientific procedures, FDA requires the same quantity and quality of safety evidence needed for food additive approval. The basis must also be generally available and accepted among qualified experts. The problem is not that GRAS has no scientific standards. It is that companies can reach conclusions without submitting them for FDA review.

Who pays, and who checks?

Companies can commission safety assessments and compensate experts supporting GRAS conclusions. Payment does not automatically invalidate their work. It does make financial interests and independence legitimate concerns.

In 2010, the Government Accountability Office called for stronger oversight and safeguards against conflicts of interest. FDA finalized guidance on GRAS panels in 2022, including recommendations to reduce bias and assess potential conflicts. However, guidance generally offers recommendations rather than legally enforceable requirements.

When a company benefits financially from a favorable safety conclusion, transparency should be a basic expectation.

FDA does review notices that companies voluntarily submit. Its response may state that it has no questions about the conclusion, that the notice provides insufficient support, or that evaluation stopped at the company’s request. Simply appearing in FDA’s GRAS inventory does not mean a substance received a favorable review.

The larger gap concerns conclusions FDA never receives. Without required notification, the agency lacks a complete picture of substances entering the food supply through this pathway. That does not prove deliberate indifference. It does reveal a serious limit on oversight.

Where Food Addiction fits

GRAS addresses the safety of a substance’s intended use. It does not certify a finished food’s nutritional value or settle whether its formulation contributes to compulsive eating.

Research on Food Addiction examines ultra-processed foods, including products high in refined carbohydrates and added fats. Researchers are investigating how these foods engage reward pathways, trigger cravings, and contribute to difficulty controlling consumption. Important questions remain about which features drive those responses.

A 2019 NIH trial illustrates why finished foods deserve attention. Twenty adults lived at a research facility and received an ultra-processed diet and an unprocessed diet for two weeks each, in random order. They could eat as much or as little as they wanted.

Participants ate about 500 additional calories daily and gained roughly two pounds during the ultra-processed phase. They lost roughly two pounds during the unprocessed phase. The small, short trial did not establish Food Addiction or identify an additive as the cause. It demonstrated that the diets affected consumption differently.

Ingredient oversight and research on Food Addiction address different questions. Both matter. Neither should become an excuse to overlook the other.

A proposed change – and a chance to comment

On August 10, 2026, FDA proposed requiring notification for certain GRAS uses. As of October 31, the change remains proposed. FDA says mandatory reporting would provide more information to the agency and the public and help identify potentially unsafe uses.

Notification would improve visibility. It would not turn GRAS into the standard food additive approval process. Knowing what companies are introducing is a necessary step toward accountability, rather than the end of the work.

Read the proposal and submit a public comment by December 9, 2026. Visit Regulations.gov and look for docket FDA-2025-N-3262. FDA’s public-comment invitation confirms the deadline and submission details.

Consumers deserve to know who reached a safety conclusion, who paid for the assessment, and whether FDA reviewed it. “Generally Recognized as Safe” should withstand those questions.

Source Materials